CANCER PIPELINE: Bristol-Myers Squibb Co. has more than a half-dozen drugs in various stages of testing against different cancers and could get a couple of approvals this year.
NEWEST DRUG: Yervoy was approved in the U.S. in March for advanced melanoma, the deadliest skin cancer, in patients who've failed on another therapy. It works by stimulating the immune system.
BRISTOL STRATEGY: Bristol's head of cancer research says Yervoy's success shows targeted immune therapies will become a standard part of cancer treatment. The company aims to be a leader in immune-based cancer treatments.